Seer (SEER) Competitors

Alpha Teknova has a beta of 0.64, meaning that its stock price is 36% less volatile than the broader market. Comparatively, Seer has a beta of 1.56, meaning that its stock price is 56% more volatile than the broader market.

Alpha Teknova presently has a consensus price target of $7.50, indicating a potential upside of 2.88%. Seer has a consensus price target of $4.00, indicating a potential upside of 92.31%. Given Seer's stronger consensus rating and higher possible upside, analysts clearly believe Seer is more favorable than Alpha Teknova.

Alpha Teknova has a net margin of -38.37% compared to Seer's net margin of -478.05%. Alpha Teknova's return on equity of -24.94% beat Seer's return on equity.

13.8% of Alpha Teknova shares are held by institutional investors. Comparatively, 75.2% of Seer shares are held by institutional investors. 13.2% of Alpha Teknova shares are held by insiders. Comparatively, 11.3% of Seer shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Alpha Teknova has higher revenue and earnings than Seer. Alpha Teknova is trading at a lower price-to-earnings ratio than Seer, indicating that it is currently the more affordable of the two stocks.

In the previous week, Seer had 6 more articles in the media than Alpha Teknova. MarketBeat recorded 9 mentions for Seer and 3 mentions for Alpha Teknova. Alpha Teknova's average media sentiment score of 0.78 beat Seer's score of -0.29 indicating that Alpha Teknova is being referred to more favorably in the media.

Simulations Plus has higher revenue and earnings than Seer. Seer is trading at a lower price-to-earnings ratio than Simulations Plus, indicating that it is currently the more affordable of the two stocks.

Seer has a beta of 1.56, meaning that its stock price is 56% more volatile than the broader market. Comparatively, Simulations Plus has a beta of 1.32, meaning that its stock price is 32% more volatile than the broader market.

Simulations Plus has a net margin of 9.88% compared to Seer's net margin of -478.05%. Simulations Plus' return on equity of 13.50% beat Seer's return on equity.

In the previous week, Seer had 4 more articles in the media than Simulations Plus. MarketBeat recorded 9 mentions for Seer and 5 mentions for Simulations Plus. Simulations Plus' average media sentiment score of 1.18 beat Seer's score of -0.29 indicating that Simulations Plus is being referred to more favorably in the news media.

75.2% of Seer shares are owned by institutional investors. Comparatively, 78.1% of Simulations Plus shares are owned by institutional investors. 11.3% of Seer shares are owned by insiders. Comparatively, 19.1% of Simulations Plus shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Seer currently has a consensus target price of $4.00, suggesting a potential upside of 92.31%. Simulations Plus has a consensus target price of $17.25, suggesting a potential downside of 5.99%. Given Seer's stronger consensus rating and higher probable upside, equities research analysts clearly believe Seer is more favorable than Simulations Plus.

Seer currently has a consensus price target of $4.00, suggesting a potential upside of 92.31%. Pacific Biosciences of California has a consensus price target of $1.83, suggesting a potential upside of 59.42%. Given Seer's stronger consensus rating and higher possible upside, analysts plainly believe Seer is more favorable than Pacific Biosciences of California.

Pacific Biosciences of California has a net margin of -82.49% compared to Seer's net margin of -478.05%. Seer's return on equity of -27.23% beat Pacific Biosciences of California's return on equity.

75.2% of Seer shares are held by institutional investors. 11.3% of Seer shares are held by company insiders. Comparatively, 3.7% of Pacific Biosciences of California shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Seer has higher earnings, but lower revenue than Pacific Biosciences of California. Pacific Biosciences of California is trading at a lower price-to-earnings ratio than Seer, indicating that it is currently the more affordable of the two stocks.

In the previous week, Seer had 7 more articles in the media than Pacific Biosciences of California. MarketBeat recorded 9 mentions for Seer and 2 mentions for Pacific Biosciences of California. Pacific Biosciences of California's average media sentiment score of 0.68 beat Seer's score of -0.29 indicating that Pacific Biosciences of California is being referred to more favorably in the news media.

Seer has a beta of 1.56, suggesting that its stock price is 56% more volatile than the broader market. Comparatively, Pacific Biosciences of California has a beta of 2.31, suggesting that its stock price is 131% more volatile than the broader market.

Standard BioTools presently has a consensus target price of $1.35, suggesting a potential upside of 89.50%. Seer has a consensus target price of $4.00, suggesting a potential upside of 92.31%. Given Seer's stronger consensus rating and higher possible upside, analysts clearly believe Seer is more favorable than Standard BioTools.

53.7% of Standard BioTools shares are held by institutional investors. Comparatively, 75.2% of Seer shares are held by institutional investors. 26.8% of Standard BioTools shares are held by company insiders. Comparatively, 11.3% of Seer shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Standard BioTools has a beta of 1.4, suggesting that its stock price is 40% more volatile than the broader market. Comparatively, Seer has a beta of 1.56, suggesting that its stock price is 56% more volatile than the broader market.

Seer has lower revenue, but higher earnings than Standard BioTools. Seer is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks.

Standard BioTools has a net margin of 100.36% compared to Seer's net margin of -478.05%. Standard BioTools' return on equity of -7.57% beat Seer's return on equity.

In the previous week, Seer had 5 more articles in the media than Standard BioTools. MarketBeat recorded 9 mentions for Seer and 4 mentions for Standard BioTools. Standard BioTools' average media sentiment score of 0.64 beat Seer's score of -0.29 indicating that Standard BioTools is being referred to more favorably in the media.